

ONLINE SUPPLEMENTARY DATA

**Supplementary Table 1.** Baseline Characteristics of All Unmatched Statin-Initiators

Baseline Characteristics	Unmatched Statin-Initiators	
	Included (n=2,863)	Excluded Due to Missing Covariates (n=475)
<b>Demographics</b>		
Age, years (mean)	64.3	63.6
Sex (% male)	24.4	26.5
BMI, kg/m <sup>2</sup> (mean)	27.5	27.4
<b>Systemic Autoimmune Rheumatic Disease (%)</b>		
Systemic lupus erythematosus	47.7	46.1
Systemic sclerosis	11.9	13.5
Sjogren's syndrome	29.6	28.2
Dermatomyositis/polymyositis	7.8	7.8
ANCA-associated vasculitis	4.7	7.1
Behcet's disease	3.9	2.9
<b>Disease Duration (years)</b>	12.4	11.6
<b>Smoking Status (%)</b>		
Current smokers	19.2	19.9
<b>Alcohol Use (%)</b>		
Current alcohol use	69.4	69.6
<b>Medication Use (%)</b>		
Aspirin	40.2	44.6
Antihypertensive Medications	72.6	74.3
Beta blockers	25.9	29.3
Calcium Channel Blockers	32.9	30.5
Nitrates	10.6	12.4
ACE Inhibitors	31.5	35.4
NSAIDs	29.9	28.0
Loop Diuretics	14.8	22.3
Thiazide	20.5	16.2
Potassium-Sparing Diuretics	5.0	7.2
Insulin	2.9	4.2
Anticoagulants	6.9	8.6
Glucocorticoids	29.4	35.4
<b>Comorbid conditions (%)</b>		
Myocardial Infarction	9.0	10.9
Ischemic Heart Disease	19.8	24.8
Peripheral Vascular Disease	3.2	4.2

Valvular Heart Disease	3.9	4.4
Stroke	7.5	9.9
Atrial Fibrillation	4.0	6.7
Hypertension	53.9	46.3
Congestive Heart Failure	4.7	4.0
Angina	9.6	11.4
Other Cardiovascular Disease	3.1	3.2
Venous Thromboembolism	6.5	4.4
Varicose Veins	11.9	9.1
Hyperlipidemia	20.3	18.7
Diabetes	17.5	14.9
CKD ( $\geq$ stage 3)	11.5	9.5
Liver Disease	4.4	3.8
Cancer	10.9	8.2
Chronic Obstructive Pulmonary Disease	6.1	6.7
Infection/Pneumonia	12.1	9.7
Depression	18.5	13.3
<b>Health Care Utilization</b>		
General Practice Visits*	15.4	13.3
Specialist Referrals*	1.2	1.1
Hospitalizations*	0.9	0.9
<b>Laboratory Measurements</b>		
Total Cholesterol (mg/dl)	235.6	239.2

\*Frequency during the past 2 years.

BMI, body mass index; NSAIDs, non-steroidal anti-inflammatory drugs; CKD, Chronic Kidney Disease.

**Supplementary Table 2.** Association Between Statin Initiation and All-Cause Mortality in Propensity Score-Matched Cohorts Excluding Systemic Autoimmune Rheumatic Disease Subgroups

Excluded Subgroup	Statin-Initiator (N=2,305)		Non-Initiator (N=2,305)		HR (95% CI)
	Deaths (N)	Mortality Rate/1,000 PY	Deaths (N)	Mortality Rate/1,000 PY	
Vasculitis*	275	25.4	314	30.9	0.82 (0.70-0.96)
Myositis**	271	25.2	317	30.9	0.82 (0.69-0.96)
SLE	173	28.8	192	34.8	0.83 (0.68-1.02)
Sjogren's syndrome	203	24.5	240	29.8	0.82 (0.68-0.99)
SSc	257	24.6	274	27.8	0.88 (0.75-1.05)

\* Vasculitis includes Behcet's disease and ANCA-associated vasculitis

\*\*Myositis includes dermatomyositis and polymyositis

SLE, systemic lupus erythematosus; SSc, systemic sclerosis; PY, person-years